Korea positioned to be global biopharma powerhouse, says industry association

Biopharma-Reporter was at CPhI Korea at the Coex centre, Seoul

Stem cells and biosimilars are driving the Korean pharma market, according to the country’s Biomedicine Industry Association KoBIA.

iStock/alice-photo

Pfizer unit Hospira and Napp broke APBI code during Remsima push

CPhI Korea in Seoul

Accelerating timelines vital to securing slice of biosimilars market, KBI

iStock/Grafner

Portola 'surprised' with CMC concerns in FDA rejection of anticoagulant candidate

iStock/s-c-s

Cost pressures turning pharma towards automation tech, says Zenith

See More Headlines

Markets & Regulations

Image: iStock/NiroDesign

Pfizer plans for October Remicade biosimilar launch, boosted by IP ruling

Image: iStock/DigitalStorm

StemCells Inc picked up by Israeli medical devices firm

Image: iStock/G0d4ather

Formycon up after Pfizer halts Lucentis biosimilar development

See More in Markets & Regulations

Upstream Processing

Image: iStock/albertobrian

GE on film: Reducing risk of leachables starts with the raw materials

Image: iStock/pichet_w

Public Patheon's $2bn warchest may bolster biologics offering, analyst

Image: iStock/arinarici

Cognate to make dendritic cell cancer vaccine in $2.2m deal with Asterias

See More in Upstream Processing

Downstream Processing

EMA says biologics developers need to be extra vigilant

EMA says biologics developers need to be extra vigilant

Piramal adds HPAPI capabilities through the acquisition of Michigan, US-based Ash Stevens. Image: Google Streetview

Piramal: $53m Ash Stevens addition ‘synergistic’ with ADC business

The expansion at Novartis' Center of Biotechnology in Huningue, France was first announced in a meeting with French officials in April. Image: Google Streetview

Novartis invests €100m to boost mAb production 70% at French biologics site

See More in Downstream Processing

Bio Developments

One analyst said any potential deal was unlikely

Rumour of Thermo Fisher Scientific $30bn offer for Illumina

Avacta's site in Wetherby, UK. Image c/o Avacta Group

Avacta opens UK facilities to bolster antibody alternative development

Image: iStock/Alkov

Antibiotic resistance most imminent threat to humanity, says bacteriophage maker

See More in Bio Developments

Popular News

Image: iStock/NiroDesign

Pfizer plans for October Remicade biosimilar launch, boosted by IP ruling

iStock/alice-photo

Pfizer unit Hospira and Napp broke APBI code during Remsima push

Image: iStock/DigitalStorm

StemCells Inc picked up by Israeli medical devices firm

Galleries

Videos

Audio

Latest Products

See more products